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Pseudomonas aeruginosa causes problematic chronic lung infections in those suffering
from cystic fibrosis. This is due to its antimicrobial resistance mechanisms and its
ability to form robust biofilm communities with increased antimicrobial tolerances. Using
novel antimicrobials or repurposing current ones is required in order to overcome
these problems. Manuka honey is a natural antimicrobial agent that has been used
for many decades in the treatment of chronic surface wounds with great success,
particularly those infected with P. aeruginosa. Here we aim to determine whether
the antimicrobial activity of manuka honey could potentially be repurposed to inhibit
pulmonary P. aeruginosa infections using two ex vivo models. P. aeruginosa isolates
(n = 28) from an international panel were tested for their susceptibility to manuka
honey and clinically relevant antibiotics (ciprofloxacin, ceftazidime, and tobramycin),
alone and in combination, using conventional antimicrobial susceptibility testing (AST).
To increase clinical applicability, two ex vivo porcine lung (EVPL) models (using alveolar
and bronchiolar tissue) were used to determine the anti-biofilm effects of manuka honey
alone and in combination with antibiotics. All P. aeruginosa isolates were susceptible to
manuka honey, however, varying incidences of resistance were seen against antibiotics.
The combination of sub-inhibitory manuka honey and antibiotics using conventional AST
had no effect on activity against the majority of isolates tested. Using the two ex vivo
models, 64% (w/v) manuka honey inhibited many of the isolates where abnormally high
concentrations of antibiotics could not. Typically, combinations of both manuka honey
and antibiotics had increased antimicrobial activity. These results highlight the potential
of manuka honey as a future antimicrobial for the treatment of pulmonary P. aeruginosa
isolates, clearing potential infection reservoirs within the upper airway.
Keywords: Pseudomonas aeruginosa, biofilms, antimicrobial susceptibility testing, manuka honey, ex vivo model,
cystic fibrosis
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INTRODUCTION
Pseudomonas aeruginosa is an opportunistic pathogen, capable
of causing infections in various immunocompromised patient
groups (de Bentzmann and Plésiat, 2011). Patients suffering with
Cystic Fibrosis (CF) are at a heightened risk of P. aeruginosa
infection (Lyczak et al., 2002). Amongst the many complications
that affect the body of CF patients, mucus build-up within
the lung results in chronic pulmonary colonization, with the
nasal cavity and upper respiratory tract acting as reservoirs
for recurrent infections (Siegel and Weiser, 2015). Up to
80% of CF patients will acquire a pulmonary P. aeruginosa
infection, an event that is linked to poor patient prognosis and
infection chronicity (Schelstraete et al., 2013). This link between
P. aeruginosa and persistence, is due, in part, to the formation of
biofilms by mucoid strains (Høiby et al., 2010).
Biofilm formation in P. aeruginosa leads to increased
antimicrobial tolerance (AMT), an extra defensive strategy on
top of the innate and acquired antimicrobial resistance (AMR)
mechanisms it possesses (El Zowalaty et al., 2015). Eradication of
P. aeruginosa from the CF lung is therefore not always possible,
even when aggressive antimicrobial treatment regimens are
used. There are few effective therapeutic options for pulmonary
P. aeruginosa infections, with many patients harboring multi-
drug resistant strains (López-Causapé et al., 2017). In order
to provide respite care for these patients, novel antimicrobial
agents with effective anti-biofilm effects must be identified
(Worthington and Melander, 2013).
Recently, researchers have sought innovative antimicrobial
strategies, utilizing natural products in order to combat AMR
(Halstead et al., 2015; Harrison et al., 2015; Moloney, 2016).
An antimicrobial agent which has demonstrable antimicrobial
and anti-biofilm activity is manuka honey (Molan, 2016; White,
2016). It is well documented in wound microbiology that manuka
honey is an effective treatment for chronic infections with
exceptional activity against a range of AMR organisms (Mandal
and Mandal, 2011; Maddocks and Jenkins, 2013). To date, two
mechanisms of action have been identified: impairment of the
cell division process described in Staphylococcus aureus, (Jenkins
et al., 2011) and disruption of the cell envelope in P. aeruginosa
(Roberts et al., 2012).
Previous manuka honey research has focussed on pathogens
associated with wounds. However, many species found in wounds
are synonymous with pulmonary infection. A recent study
showed that manuka honey is capable of inhibiting the growth
of multiple P. aeruginosa isolates (n = 56) of pulmonary origin
(Jenkins et al., 2015), however, the methodologies used better
represented acute infections as opposed to chronic biofilm-
infections (European Committee for Antimicrobial Susceptibilty
Testing , 2003). To ensure the best translational applicability for
novel treatments, models that more accurately represent in vivo
conditions are required (Roberts et al., 2015).
Recently, two ex vivo porcine lung (EVPL) models for the
study of pulmonary P. aeruginosa biofilms have been described
(Harrison et al., 2015; Harrison and Diggle, 2016). These provide
a spatially structured in vivo environment with similar nutrient
cues to those identified in CF sputum, allowing bacteria to
form biofilms similar to those found in chronic lung infection
(Palmer et al., 2005). This study is the first to utilize these
more relevant models to determine the inhibitory efficacy of
relevant antibiotics and medical grade manuka honey against a
wide range of pulmonary P. aeruginosa isolates selected from
an international reference panel (De Soyza et al., 2013). This
focussed panel of isolates allows a wide range of pheno- and
geno-types to be extensively tested, covering the wide diversity
of P. aeruginosa isolates observed in the CF lung from commonly
studied clones, to highly transmissible strains.
MATERIALS AND METHODS
Ethics Statement
Materials required for the EVPL model were sourced from a local
butcher as waste products of the food industry.
Manuka Honey
Gamma-irradiated medical grade manuka honey (Medihoney;
Integra Life Sciences) with a Unique Manuka Factor (UMF)
rating of 12+ was used throughout.
Bacterial Strains and Culture Conditions
Twenty eight P. aeruginosa Reference Panel (PaRP) isolates
(De Soyza et al., 2013), were selected and covered a wide range
of phenotypically and genotypically diverse isolates. Isolates were
recovered from frozen stocks on Cation Adjusted (10 mg/L
Mg2+ and 20 mg/L Ca2+) Mueller Hinton Agar (CA-MHA)
for 24 h at 37◦C. Log-phase and stationary phase cells were
created by transferring single colonies to aliquots of Cation
Adjusted Mueller Hinton Broth (CA-MHB) for 6 and 24 h,
respectively, at 37◦C.
Minimum Inhibitory Concentrations
(MICs) for Antimicrobial Agents
The Minimum Inhibitory Concentration (MIC) of manuka
honey and clinically relevant antibiotics (Cystic Fibrosis Trust ,
2009), was determined in accordance with microbroth dilution
standards set out by the European Committee on Antimicrobial
Susceptibility Testing (EUCAST; European Committee for
Antimicrobial Susceptibilty Testing , 2003). Various doubling
dilutions of manuka honey (1–32% w/v), ciprofloxacin (0.002–
128 µg/ml), ceftazidime 0.03–2048 µg/ml), and tobramycin
(0.016–1024 µg/ml) were used to determine the MICs. All results
were derived from triplicate biological replicas.
Determining Potential Interaction
Between Antimicrobial Agents
To test for interactions between manuka honey and antibiotics,
sub-inhibitory concentrations of honey (0.5, 0.25, and 0.125
of the MIC) were supplemented with various concentrations
of antibiotics using a checkerboard methodology. Fractional
Inhibitory Concentration Indices (FICI), which determine
interplay between two antimicrobial agents were calculated.
Mean FICI values from each of the sub-inhibitory manuka
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honey concentrations were used to allow a comprehensive
dose-response analyses of total inhibition between the
two antimicrobial agents and interpreted as: “synergistic”
(FICI ≤ 0.5), “antagonistic” (FICI > 4.0), and “no interaction”
(FICI > 0.5–4.0) (Odds, 2003). All results were derived from
triplicate biological replicas for each of the sub-inhibitory
manuka honey concentrations.
Efficacy of Manuka Honey and
Antibiotics Against PaRP Biofilms Grown
in an ex vivo Porcine Lung (EVPL)
Alveolar Model
The anti-biofilm effects of manuka honey and antibiotics were
identified using an EVPL alveolar model (Harrison et al., 2014).
Briefly, stationary growth phase bacterial cells were washed twice
with Phosphate Buffered Saline (PBS) and re-suspended in an
Artificial Sputum Media (ASM; Palmer et al., 2007) supplemented
with 50 µg/ml ampicillin (ASMAmp) to a final cell density
of ∼2 × 105 cells/ml. Triplicate cubes (5 mm3) of EVPL
alveolar tissue were dissected from the ventral surface of the left
caudal lobe, washed three times with 1 ml Cell Culture Media
supplemented with 50 µg/ml ampicillin (50% v/v RPMI 1640
and Dulbecco’s modified Eagle medium [DMEM]), and once with
1 ml ASMAmp. EVPL alveolar tissue cubes were placed on a bed
of solidified ASMAmp (using 0.8% agarose) in 24-well microtitre
plates, submerged in 0.5 ml ASMAmp and inoculated with 50 µl
of cells using a 30-gauge needle. Cubes of EVPL alveolar tissue
were incubated at 37◦C. After 24 h, the cubes were rinsed with
1 ml PBS, removing loosely adhered cells, and treated with 0.5 ml
of 0% (ASMAmp), 32%, or 64% w/v manuka honey supplemented
with/without antibiotics (128 µg/ml ciprofloxacin, 2048 µg/ml
ceftazidime, or 1024 µg/ml tobramycin) for 16 h. Increased
concentrations of antimicrobial solutions were selected due to
biofilms being inherently more tolerant of antimicrobial agents.
Cubes of EVPL alveolar tissue were then rinsed with 1 ml PBS,
and homogenized in 500 µl PBS with 7 mm × 2.8 mm metal
beads using a Beadbug Microtube homogeniser (Benchmark
Scientific) at 4000 rpm for 40 s. Total viable counts (TVCs)
were completed for biofilm cells within in the homogenized
samples. Biological replica data was obtained using triplicate
independent porcine lungs obtained from the local butcher on
separate occasions.
Efficacy of Manuka Honey and
Antibiotics Against Certain PaRP
Biofilms Grown in an EVPL
Bronchiole Model
In addition to the anti-biofilm effects studied using an EVPL
alveolar model (simulating lower respiratory tract infections), the
effect of manuka honey and antibiotics was studied against PaRP
isolate #1 (LES B58, a representative transmissible strain), #17
(PAO1; a representative reference strain), and #28 (NH57388A;
a mucoid phenotypically diverse strain) in an EVPL model using
bronchiole tissue (simulating upper respiratory tract infections)
(Harrison and Diggle, 2016). The transition from alveolar tissue
to bronchiole tissue was to aid visualization of the tissue surface,
as infection with P. aeruginosa isolates was highly destructive
to alveolar tissue. Methodologies similar to the EVPL alveolar
model were used, however, bronchiole sections were cleaned of
alveolar tissue and dissected into triplicate 5 mm2 sections. These
were washed, inoculated, and treated as above. TVCs of cells
surviving treatment with each of the antimicrobial agents were
determined; parallel samples for PaRP isolate #1 were prepared
for Scanning Electron Microscopy (SEM) by fixing overnight
in 2.5% [v/v] glutaraldehyde (4◦C). Samples were rinsed in
distilled water (x3) prior to critical-point drying, employing a
gradual ascending series of ethanol dehydration steps. Finally,
the samples underwent three changes in hexamethyldisilazane
until the solution had evaporated. Samples were then sputter-
coated with gold and imaged using the Tescan Vega SEM at 4 kV.
SEM images were then processed in ImageJ software. Biological
replica data was obtained using triplicate independent porcine
lungs obtained from the local butcher on separate occasions.
Statistical Analysis
Analysis of variance (ANOVA) was used to test the main effects
of manuka honey and antibiotics on bacterial load with Dunnett’s
post hoc test applied where applicable.
RESULTS
All PaRP isolates, using conventional antimicrobial susceptibility
testing (AST), were inhibited by 16% or 32% (w/v) manuka
honey (n = 22 and 6, respectively; Figure 1A). The majority
of isolates with Minimum inhibitory concentration values of
32% w/v manuka honey (n = 5) were paired and/or sequential
isolates taken at varying times from the same source (De Soyza
et al., 2013). MIC values for ciprofloxacin, ceftazidime, and
tobramycin varied above and below the EUCAST breakpoints
(Figures 1B–D, respectively). The majority of isolates were
sensitive to tobramycin (n = 20) and resistant to ciprofloxacin
(n = 17) and ceftazidime (n = 15). PaRP isolate #1, 4, 15,
and 41 were shown to be resistant to all tested antibiotics,
however, they were inhibited with a lower manuka honey
concentration [16% (w/v)].
Fractional inhibitory concentration indices values showed
that manuka honey and ciprofloxacin had no interactive effects
against the majority of PaRP isolates (n = 25; Figure 2A).
Some isolate-specific interactions, dependent upon manuka
honey concentration, were observed when FICI values
crossed interaction “breakpoints” indicative of antagonism
and synergism. As an example; various manuka honey and
ciprofloxacin combinations worked synergistically against PaRP
isolate #41 (Supplementary Figure 1) which was deemed
resistant to ciprofloxacin (Figure 1B). FICI values for manuka
honey and ceftazidime indicated no interaction between the two
antimicrobial agents for the majority of isolates tested (n = 24;
Figure 2B). Strain-specific interactions were again observed
with some FICI values crossing interaction “breakpoints”
indicating antagonism and synergism. As an example; 0.125 MIC
manuka honey and ceftazidime worked synergistically against
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FIGURE 1 | Minimum Inhibitory Concentrations (MICs) of P. aeruginosa Reference Panel (PaRP) isolates associated with Cystic Fibrosis (CF) to manuka honey
(expressed as % [w/v]; A) and three clinically relevant antibiotics (expressed as µg/ml); ciprofloxacin (B), ceftazidime (C) and tobramycin (D). PaRP strains found to
be sensitive/resistant to the antibiotics tested (B–D), based on EUCAST breakpoints (dashed horizontal line), are colored light/dark gray, respectively (this does not
apply to manuka honey (A) where there is no EUCAST breakpoint).
PaRP isolate #4 (Supplementary Figure 2) which was deemed
resistant to ceftazidime (Figure 1C). Interactions between
manuka honey and tobramycin were more varied, despite there
being no discernible interaction against the majority of PaRP
isolates tested (n = 19; Figure 2C). This was because FICI
values for a larger proportion of isolates crossed antagonistic
breakpoints due to two of the sub-inhibitory concentrations of
manuka honey having antagonistic FICI values (Supplementary
Figure 3). Synergism between tobramycin and 0.25 MIC manuka
honey was observed against the tobramycin resistant isolate
PaRP #41 (Supplementary Figure 3). Interestingly instances
of synergy and antagonism, pushing the mean FICI value over
the respective breakpoints were observed when low and high
sub-inhibitory concentrations of manuka honey (0.125 and 0.5
MIC, respectively) were used (Supplementary Figure 3).
In the EVPL alveolar tissue, all PaRP isolates produced high
cell density biofilms (>1 × 107 cfu/5mm3; Figure 3A) with
varying visible degrees of exopolysaccharide production
(Supplementary Figure 4). Overall, manuka honey
demonstrated significant inhibition of multiple PaRP isolates
[F(2,168) = 116.3, p < 0.0001], with a range of log-fold reductions
being observed in the presence of 32% w/v manuka honey
(strain dependent), in addition to the complete inhibition
of multiple (n = 12) isolates with 64% w/v manuka honey
(Figure 3A). This observation was not seen when ]ciprofloxacin
or ceftazidime were used alone (despite the high concentrations),
however, tobramycin was effective at inhibiting the majority
of isolates (n = 17; Figure 3D). When used in combination
with ciprofloxacin, ceftazidime or tobramycin, manuka honey
induced further statistically significant reductions in cellular
viability [F(2,168) = 27.68, p< 0.0001, F(2,168) = 27.42, p< 0.0001,
and F(2,168) = 24.61, p < 0.0001, respectively], with an increased
incidence rate of total inhibition increased (n = 21, 27, and 28,
respectively). It was noted that against some PaRP strains, the
addition of various antibiotics had a negative effect on 32% (w/v)
manuka honey, slightly reducing its inhibitory efficacy, however,
viability remained below that seen in control conditions with
no treatment (Figure 3; e.g., ceftazidime and 32% w/v manuka
honey had reduced efficacy against PaRP #1 compared to manuka
honey alone, however, this activity was better than control).
Three representative PaRP isolates grown on EVPL bronchiole
tissue sections with ASM demonstrated dense biofilm growth
(>1 × 108 cfu/5 mm2; Figure 4). Manuka honey at 64%
w/v completely inhibited cellular viability with and without
antibiotics, with 3–4 log reductions observed in samples treated
with 32% w/v manuka honey (Figure 4). Combinations of
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FIGURE 2 | Fractional Inhibitory Concentration Index (FICI) of sub-inhibitory manuka honey concentrations supplemented with one of three clinically relevant
antibiotics; ciprofloxacin (A), ceftazidime (B) and tobramycin (C). The interaction between manuka honey and antibiotics were interpreted as ’synergistic (FICI < 0.5),
“antagonistic” (FICI > 4.0), and “no interaction” (FICI > 0.5–4.0).
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FIGURE 3 | Viability of P. aeruginosa Reference Panel (PaRP) isolates grown in ex vivo Porcine Lung (EVPL) alveolar tissue for 24 h and treated with ASM (A),
ciprofloxacin (B), ceftazidime (C), and tobramycin (D) supplemented with 32 and 64% w/v manuka honey for 16 h. Dashed horizontal lines indicate the detection
level of the EVPL model. Error bars denote Standard Deviation.
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FIGURE 4 | Viability of three P. aeruginosa Reference Panel (PaRP) isolates; #1, #17, and #28, grown in ex vivo Porcine Lung (EVPL) bronchiolar tissue for 24 h and
treated with ASM or clinically relevant antibiotics (Cip; Ciprofloxacin, Tob; Tobramycin, and Caz; Ceftazidime) supplemented with 32% and 64% (w/v) manuka honey
for 16 h. Dashed horizontal lines indicate the detection level of the model. Error bars denote Standard Deviation. Varying levels of statistical significance denoted by
∗, ∗∗, and ∗∗∗ (P≤0.05, 0.001, and 0.0001 respectively).
ciprofloxacin and manuka honey (32% w/v) caused a marginal
(less than 1 log-fold difference), yet significant (P < 0.05)
increase in cellular numbers compared to untreated samples
(Figure 4). Conversely, ceftazidime and 32% (w/v) manuka
honey caused significant reductions in viability (P < 0.001),
however, the extent of inhibition observed was strain-dependent,
with only marginal reductions against PaRP #17 (Figure 4).
As tobramycin completely inhibited two of the three isolates
tested, only one isolate could be studied. The viability of PaRP#1
was reduced when 64% manuka honey and tobramycin were
combined (Figure 4).
Comparative SEM imaging of the EVPL bronchiole tissue
infected with PaRP isolate #1 was employed (Figure 5), with
concurrent growth of biofilm cells (compared to TVC data)
under control conditions (ASM only). In the presence of
both concentrations of manuka honey cells were not observed
on the surface of bronchioles. Ceftazidime was selected as a
representative antibiotic for testing here due to the different
effects observed against the selected isolates. In the presence of
ceftazidime, bacterial cells were present, however, the addition
of varying manuka honey concentrations resulted in the loss of
cells from the tissues imaged. It should also be noted that in
the presence of 64% (w/v) manuka honey, differences in tissue
structure were observed.
DISCUSSION
Pulmonary P. aeruginosa infections are difficult to treat, due
to its various AMR and AMT capabilities and the constraints
surrounding the effective delivery of antimicrobial agents (Lee
and Yoon, 2017). It is therefore crucial that novel antimicrobial
agents are identified, especially those with anti-biofilm activity.
This study demonstrates that manuka honey was effective at
inhibiting a wide range of P. aeruginosa isolates (22) associated
with CF infection; building on the findings of a previous study
(Jenkins et al., 2015). For the first time, it was established that
manuka honey reduced the viability of various P. aeruginosa
isolates in an ex vivo infection model (where clinically relevant
antibiotics could not), allowing a realistic assessment of the ability
of manuka honey to inhibit biofilms in more realistic tissue types.
Previous studies (Maddocks et al., 2012; Lu et al., 2014; Liu et al.,
2018) have shown antimicrobial efficacy of manuka honey against
biofilms grown using conventional in vitro methods, however,
biofilms grown using ex vivo models and ASM are thought to
be more representative of clinical biofilms, unlike those formed
using conventional in vitro methods and microbiological media
(Roberts et al., 2015).
Minimum inhibitory concentration testing was completed
using methods that are typical in a clinical setting, and whilst
it is believed that these methods (which reply on the use of
planktonic cells) do not convey what is seen during chronic
infection (biofilms) (Roberts et al., 2015), they represent gold
standard practice. Whilst methods looking into the Minimum
Biofilm Inhibition Concentration (MBIC) could have been used,
they are not done routinely in clinic and would not provide any
additional information as the MIC and MBIC of manuka honey
have been previously observed to be similar (Liu et al., 2015).
Conventional MIC values were higher than those seen previously,
and is thought to be due to a change in the methodologies,
whereby doubling dilutions were used (so as to be in line
with EUCAST methodologies) instead of percentage increments
(Jenkins et al., 2015). Combining manuka honey with antibiotics
yielded varied results based on the sub-inhibitory concentration
of manuka honey used, the combined antibiotic, the strain
of P. aeruginosa and the method used (conventional methods
vs. the use of the ex vivo model). For the majority of PaRP
isolates tested via conventional methods it appeared that manuka
honey was non-interactive with the three antibiotics tested,
however, some strain specific antagonism and synergism was
observed, a stark contrast to previous studies where synergism
was widespread (Mandal and Mandal, 2011; Jenkins and Cooper,
2012; Jenkins et al., 2015). The absence of antagonism in the
majority of isolates suggests manuka honey could be considered
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FIGURE 5 | Scanning Electron Microscopy (SEM) images of P. aeruginosa Reference Panel (PaRP) isolate #11 (LES B58) recovered from ex vivo Porcine Lung
(EVPL) bronchiole tissue samples grown in Artificial Sputum Media (ASM) with/without 2048 µg/ml ceftazidime and supplemented with/without 32/65% (w/v)
manuka honey for 16 h. Images show bacteria cells (red arrows) and their subsequent inhibition with increasing antimicrobial concentrations. Scale bar = 20 µm.
for use alongside conventional antibiotic treatment regimens.
In the ex vivo models, combinations of manuka honey and
clinically relevant antibiotics had anti-biofilm efficacy, reducing
viability for the majority of isolates tested, with total inhibition
observed in many instances. This puts manuka honey in a strong
position as a potential novel therapeutic for chronic upper airway
infections, especially where AMR is observed, however, there are
some limitations to the ex vivo models. Despite similar nutrient
cues being used, nutrient availability may differ due to the lack
of thick mucus. The physical surface structures of the tissue may
differ slightly, especially if it were to degrade during infection
which might not be observed during in vivo infection of a cystic
fibrosis lung.
When considering the use of manuka honey for the treatment
of pulmonary infections, ease of application, subsequent
reapplications and potential diluting effects are difficult to
predict. During interaction studies, multiple sub-inhibitory
concentrations of manuka honey were used, allowing dilution
effects to be identified. Not only does this allow the efficacy
of the manuka honey to be determined at sub-inhibitory
concentrations when combined with antibiotics, but identifies
any potential problems arising from these combinations. It
is critical to take such observations into consideration before
progressing into a clinical setting as many of these patients
will be undergoing extensive antimicrobial therapy. The specific
instances of antagonism at low sub-inhibitory concentrations,
is most likely due to the sugars acting as a carbon source,
therefore inhibitory concentrations must be maintained. The
use of doubling dilutions might have exacerbated this, with
previous studies (Roberts et al., 2012; Jenkins et al., 2015)
opting for minor percentage reductions in concentrations
which does not necessarily convey the range of dilutions that
may be encountered in vivo. As the reference panel used
within this study covers the wide strain diversity seen for
P. aeruginosa from those that are highly transmissible to those
that are extremely virulent, effects against individual strains
should also be considered in addition to the overarching
effects on the species as a whole. For instance, the synergism
of some manuka honey and antibiotic combinations against
specific antimicrobial resistant strains (e.g., ciprofloxacin and
tobramycin against PaRP isolate #41) suggests combinational
therapy could have potential therapeutic benefit, albeit under
stringent conditions and may be of benefit where other
treatment options fail.
In light of increasing AMR, repurposing antimicrobial agents
may provide new treatment options for difficult to treat
infections. In this study we have demonstrated the antibacterial
and anti-biofilm effects of manuka honey (above the effect seen
with antibiotics when used alone) against P. aeruginosa grown
in two ex vivo models, suggesting potential for manuka honey to
be re-purposed from its original use as a wound dressing. During
routine clinical practice, biofilm-based methods for antimicrobial
testing are not used, primarily due to a lack of relevance when
it comes to patient prognosis (Coenye et al., 2018), however,
they are useful in academic research for the identification of
anti-biofilm effects, especially when they better replicate chronic
infections and their associated challenges (Waters and Ratjen,
2017). Whilst the anti-bacterial efficacy of manuka honey in
an ex vivo biofilm model simulating chronic lung infections
has been demonstrated, an obvious limitation when it comes
to clinical applicability of manuka honey for the treatment
of pulmonary infection is delivery. Firstly, Nebulisation of
antimicrobials can be both difficult and inefficient, with lower
final concentrations (13–64% of the original dose) in the lung
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environment (Bassetti et al., 2016), therefore manuka honey
is unlikely to reach the lung at 64% (w/v) in its current
formulation. Concentrations in the region of 40% (w/v) could
be achievable; however, efficacy at this concentration needs
to be experimentally tested. This potentially brings its own
challenges as manuka honey can exert in vitro toxicity on
human cells (Yabes et al., 2017). The differences between
EVPL bronchiole tissue in the presence of 64% (w/v) manuka
honey may be subject to these similar “in vitro” effects,
however, the negative effects observed in vitro do not necessarily
occur in vivo whereby 100% manuka honey is used on
open wounds with positive effects, increasing wound healing
(Mohamed et al., 2015). Alternatively higher concentration
of manuka honey could be readily incorporated into a sinus
rinse solution and be used to clear sino-nasal cavity infection
reservoirs, preventing the migration of bacteria from the upper
airway into the lung (Siegel and Weiser, 2015), and affording
terminal CF patients the opportunity to undergo lifesaving
lung transplantations.
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